The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial.

ABSTRACT:

Background

Aging is associated with progressive declines in immune responses leading to increased risk of severe infection and diminished vaccination responses. Influenza (flu) is a leading killer of older adults despite availability of seasonal vaccines. Geroscience-guided interventions targeting biological aging could offer transformational approaches to reverse broad declines in immune responses with aging. Here, we evaluated effects of metformin, an FDA approved diabetes drug and candidate anti-aging drug, on flu vaccination responses and markers of immunological resilience in a pilot and feasibility double-blinded placebo-controlled study.

Results

Healthy older adults (non-diabetic/non-prediabetic, age: 74.4 ± 1.7 years) were randomized to metformin (n = 8, 1500 mg exte

SUBMITTER: Martin DE 

PROVIDER: S-EPMC10152024 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature